Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Satraplatin Pain For GPC As Other Shoe Drops

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene backs out of overseas deal for failed prostate-cancer chemo.

You may also be interested in...



GPC Biotech To Cut 38 Percent Of Workforce

Latest action comes after the German drug maker announced a restructuring last year due to a Phase III setback with satraplatin.

Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase

Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.

GPC Biotech Plans Restructuring To Cut Costs Following SPARC Failure

German firm is planning workforce reductions after satraplatin did not show a survival benefit in prostate cancer patients

Related Content

Topics

UsernamePublicRestriction

Register

PS068305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel